Academic Journal
Early-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation.
| Τίτλος: | Early-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation. |
|---|---|
| Συγγραφείς: | Burul G; Department of Hematology, İstanbul Başakşehir Çam and Sakura City Hospital, G-434 Street No: 2L, Basaksehir, Istanbul, 34480, Turkey. gokhanburul@hotmail.com., Karaoglan Ç; Department of Pathology, İstanbul Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey., Bektaş E; Department of Rheumatology, İstanbul Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey., Bes C; Department of Rheumatology, İstanbul Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey., Kaynar L; Department of Hematology, Medipol University, Istanbul, Turkey., Serin İ; Department of Hematology, İstanbul Başakşehir Çam and Sakura City Hospital, G-434 Street No: 2L, Basaksehir, Istanbul, 34480, Turkey., Öngören Ş; Department of Hematology, İstanbul Başakşehir Çam and Sakura City Hospital, G-434 Street No: 2L, Basaksehir, Istanbul, 34480, Turkey. |
| Πηγή: | Journal of hematopathology [J Hematop] 2026 Oct 06; Vol. 19 (1). Date of Electronic Publication: 2026 Oct 06. |
| Τύπος έκδοσης: | Journal Article; Case Reports |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer Country of Publication: Germany NLM ID: 101491976 Publication Model: Electronic Cited Medium: Internet ISSN: 1865-5785 (Electronic) Linking ISSN: 18655785 NLM ISO Abbreviation: J Hematop Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Berlin ; Heidelberg : Springer |
| Ιατρικοί όροι (MeSH): | Orbital Cellulitis*/diagnosis , Orbital Cellulitis*/therapy , Hematopoietic Stem Cell Transplantation*, Ubiquitin-Activating Enzymes/genetics ; Humans ; Male ; Adult ; Diagnosis, Differential ; Transplantation, Homologous ; Syndrome ; Treatment Outcome ; Myelodysplastic Syndromes ; Skin Diseases, Genetic |
| Περίληψη: | Background: VEXAS syndrome is a somatic autoinflammatory disorder caused by UBA1 mutations in hematopoietic progenitor cells, typically affecting older men and characterized by systemic inflammation and hematologic abnormalities. Early-onset cases are extremely rare. Case Presentation: We report a 25-year-old male patient presenting with recurrent fever, weight loss, arthralgia, and inflammation mimicking orbital cellulitis. Imaging demonstrated orbital soft tissue inflammation. Laboratory investigations revealed macrocytic anemia, leukopenia, thrombocytopenia, and elevated inflammatory markers; FDG-PET/CT showed splenomegaly and hypermetabolic lymphadenopathy. Bone marrow examination revealed hypercellularity, multilineage morphological abnormalities, and vacuolated blasts. Following exclusion of infectious and classical autoinflammatory diseases, the somatic UBA1 c.121A > G (p.Met41Val) mutation confirmed VEXAS syndrome. The patient initially responded to corticosteroids but subsequently developed refractory disease and progressive pancytopenia despite tocilizumab therapy. He underwent allogeneic hematopoietic stem cell transplantation from a 10/10 HLA-matched sibling donor using a myeloablative conditioning regimen. At 3 months post-transplantation, 99% donor chimerism and hematologic remission were achieved. Conclusion: VEXAS syndrome should be considered in young adults presenting with unexplained systemic inflammation and cytopenias, even with atypical manifestations such as orbital cellulitis. Early genetic evaluation is crucial for diagnosis, and allogeneic stem cell transplantation may provide effective disease control in refractory cases. (© 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| Competing Interests: | Declarations. Funding: Funding not applicable. Conflict of interest: The authors declare that they have no conflicts of interest relevant to this article. Ethical approval: For this type of study, formal ethical approval was not required. Consent for publication: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. |
| References: | Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383(27):2628–2638. https://doi.org/10.1056/NEJMoa2026834. (PMID: 10.1056/NEJMoa2026834331081017847551) Schulman BA, Harper JW (2009) Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 10(5):319–331. https://doi.org/10.1038/nrm2673. (PMID: 10.1038/nrm2673193524042712597) Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E et al (2022) Further characterization of clinical and laboratory features of VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol 186(3):564–574. https://doi.org/10.1111/bjd.20805. (PMID: 10.1111/bjd.2080534632574) Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK et al (2021) Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 5(16):3203–3215. https://doi.org/10.1182/bloodadvances.2021004976. (PMID: 10.1182/bloodadvances.2021004976344275848405186) Koster MJ, Kourelis T, Reichard KK, Beck DB, Liewluck T, Milone M et al (2021) Clinical heterogeneity of the VEXAS syndrome: a case series. Mayo Clin Proc 96(10):2653–2659. https://doi.org/10.1016/j.mayocp.2021.06.006. (PMID: 10.1016/j.mayocp.2021.06.00634489099) Sanchez-Hernandez BE, Calderon-Espinoza I, Martin-Nares E (2024) Challenging the paradigm: a case of early-onset VEXAS syndrome. Rheumatology (Oxford) 63(3):e99–e100. https://doi.org/10.1093/rheumatology/kead506. (PMID: 10.1093/rheumatology/kead50637740251) Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM et al (2021) Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol 73(10):1886–1895. https://doi.org/10.1002/art.41743. (PMID: 10.1002/art.417433377907413539413) Koster MJ, Lasho TL, Olteanu H, Reichard KK, Mangaonkar A, Warrington KJ, Patnaik MM (2024) VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management. Am J Hematol 99(2):284–299. https://doi.org/10.1002/ajh.27156. (PMID: 10.1002/ajh.2715637950858) Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H et al (2022) Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 140(13):1496–1506. https://doi.org/10.1182/blood.2022016985. (PMID: 10.1182/blood.2022016985357934679523373) Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L et al (2022) Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv 6(3):998–1003. https://doi.org/10.1182/bloodadvances.2021004749. (PMID: 10.1182/bloodadvances.2021004749347149148945317) |
| Contributed Indexing: | Keywords: Allogeneic hematopoietic stem cell transplantation; Ocular inflammation; Orbital cellulitis; UBA1 mutation; VEXAS syndrome |
| Substance Nomenclature: | EC 6.2.1.45 (Ubiquitin-Activating Enzymes) |
| SCR Disease Name: | VEXAS syndrome |
| Entry Date(s): | Date Created: 20261006 Date Completed: 20261006 Latest Revision: 20261006 |
| Update Code: | 20261007 |
| DOI: | 10.1007/s12308-026-00741-2 |
| PMID: | 42836952 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1865-5785 |
|---|---|
| DOI: | 10.1007/s12308-026-00741-2 |